Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Target Price at $102.70

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average rating of “Hold” by the twenty-three brokerages that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $102.70.

Several research firms have weighed in on ZBH. JPMorgan Chase & Co. cut their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a report on Wednesday, April 29th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Stifel Nicolaus cut their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Finally, Wells Fargo & Company decreased their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZBH. M&T Bank Corp grew its position in Zimmer Biomet by 15,705.6% during the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock worth $321,158,000 after buying an additional 3,548,998 shares in the last quarter. Norges Bank acquired a new stake in Zimmer Biomet during the fourth quarter worth about $221,234,000. Franklin Resources Inc. grew its position in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after buying an additional 2,017,857 shares in the last quarter. Auto Owners Insurance Co grew its position in Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after buying an additional 1,987,362 shares in the last quarter. Finally, Dodge & Cox grew its position in Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after buying an additional 1,118,710 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

NYSE ZBH opened at $88.13 on Friday. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The stock’s 50-day moving average is $87.24 and its two-hundred day moving average is $90.13. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market cap of $17.05 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 2.59 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same period last year, the company earned $1.81 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts anticipate that Zimmer Biomet will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.